RAHWAY, N.J., September 26, 2025 – Merck Animal Health, known as MSD Animal Health outside the U.S. and Canada and a division of Merck & Co., Inc., announced new safety and efficacy data for its injectable formulation of BRAVECTO® (fluralaner) during the World Small Animal Veterinary Association (WSAVA) Congress held in Rio De Janeiro, Brazil. The company also hosted educational symposia covering vaccine protocols, vector-borne diseases, and preventive care in companion animals.
The new studies highlight that a single injectable dose of BRAVECTO 365 provides up to one year of flea and tick protection in dogs, with rapid onset of action and no treatment-related adverse effects.
Science Significance
Merck Animal Health’s data underscores its leadership in advancing companion animal science. The study “One-Year Study on the Efficacy of BRAVECTO 365 Against Fleas and Rhipicephalus sanguineus Ticks on Dogs” confirmed 97% efficacy against major flea and tick species for a full 365 days. Importantly, protection remained consistent even after repeated parasite challenges. A second study highlighted BRAVECTO 365’s rapid onset, showing 95.4% efficacy within 72 hours of administration against the brown dog tick, a vector of significant parasitic diseases. These findings reinforce BRAVECTO’s role as a scientifically validated, long-term ectoparasite control solution for companion animals. The company also showcased scientific symposia focused on tailored vaccination schedules, maternal antibody interference, and One Health strategies integrating human, animal, and environmental health.
Regulatory Significance
The injectable formulation of BRAVECTO has steadily expanded its regulatory footprint since its initial approval in Australia and New Zealand (2023), followed by the European Union (2024), and the United States in 2025. It is now registered in more than 50 countries worldwide under brand names including BRAVECTO® QUANTUM, BRAVECTO® Injectable, and BRAVECTO® 365. This broad regulatory acceptance highlights global confidence in the product’s safety, efficacy, and manufacturing standards. The company’s consistent engagement with regulatory authorities demonstrates the robust clinical and safety data underpinning its approvals, as well as compliance with evolving veterinary pharmaceutical standards.
Advertisement
Business Significance
Merck Animal Health’s BRAVECTO portfolio represents one of the strongest revenue drivers in the global companion animal segment. With a product line that spans chews, topicals, and injectables, the company continues to diversify delivery formats while capturing multiple markets. The injectable version—now branded BRAVECTO 365—offers a competitive advantage in client convenience and veterinary compliance, reducing treatment frequency to once yearly. This innovation is expected to strengthen Merck’s market share in the rapidly growing flea and tick control sector, projected to surpass $3 billion globally by 2028. By linking its innovations to continuing education programs at WSAVA, Merck Animal Health also enhances brand trust and loyalty among veterinarians, a critical stakeholder group influencing prescribing behaviors.
Patients’ Significance
For companion animals and their caregivers, BRAVECTO 365 represents a meaningful improvement in parasite control and overall pet health. One injection provides year-round protection from fleas and ticks, eliminating the need for monthly dosing and reducing the risk of missed treatments. This advantage directly translates into improved compliance, better protection against zoonotic and vector-borne diseases, and greater peace of mind for pet owners. Additionally, the product’s rapid onset of action minimizes early parasite burdens, enhancing both comfort and safety for dogs during peak tick exposure periods. The educational symposia at WSAVA further reinforce the company’s commitment to promoting lifelong wellness strategies, including personalized vaccination protocols and integrated One Health approaches.
Policy Significance
Merck Animal Health’s launch of injectable BRAVECTO 365 demonstrates the importance of global alignment in veterinary pharmaceutical policies. By securing multi-region approvals and CE marks, the company sets a precedent for regulatory harmonization in companion animal therapeutics. Furthermore, the discussions at WSAVA echo broader public health priorities. As pets live increasingly close to humans, parasite control and zoonotic disease prevention intersect with One Health frameworks championed by global health authorities. Policymakers and veterinary stakeholders are encouraged to integrate these scientific advances into national and international preventive care guidelines.
Transaction Highlights
Merck Animal Health presented pivotal data on BRAVECTO® 365, confirming sustained 365-day protection against fleas and ticks with no treatment-related adverse effects. The injectable formulation, now available under the brand names BRAVECTO® QUANTUM, BRAVECTO® Injectable, and BRAVECTO® 365, has achieved approvals in more than 50 countries, including Australia, New Zealand, the European Union, and the United States. The latest studies also demonstrated the rapid onset of efficacy, showing 95.4% tick control within 72 hours of administration, significantly reducing the risk of vector-borne disease transmission. Complementing these scientific results, Merck Animal Health highlighted its commitment to veterinarian education through symposia at WSAVA, focusing on personalized vaccination strategies, One Health approaches, and the necessity of year-round ectoparasite control. The BRAVECTO franchise remains a core business driver for Merck Animal Health, further strengthening its global revenue growth in the companion animal health market.
Source: Merck & Co., Inc. Press Release
